Cartesian Therapeutics (RNAC) Projected to Announce Quarterly Earnings on Thursday

Key Points

• Cartesian Therapeutics is expected to report quarterly results before the market opens Thursday, with analysts forecasting a loss of $1.02 per share and revenue of approximately $0.16 million.
• The clinical-stage biotechnology company previously reported quarterly EPS of $0.46, beating expectations by $1.34. Analysts project full-year and next-year losses of $3.15 and $4.14 per share, respectively.
• RNAC shares opened at $6.69, well below the analyst consensus price target of $32.60. Despite mixed ratings—including one sell rating—overall analyst sentiment is “Moderate Buy,” while the company advances its mRNA cell-therapy platform and lead candidate Descartes-08.

Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) will likely be announcing its results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($1.02) per share and revenue of $0.16 million for the quarter.

Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $0.46 earnings per share for the quarter, beating analysts' consensus estimates of ($0.88) by $1.34. On average, analysts expect Cartesian Therapeutics to post ($3.15) EPS for the current fiscal year and ($4.14) EPS for the next fiscal year.

Cartesian Therapeutics Price Performance

RNAC stock opened at $6.69 on Thursday. Cartesian Therapeutics has a one year low of $5.60 and a one year high of $11.00. The stock has a market cap of $202.37 million, a PE ratio of -1.13 and a beta of 0.65. The firm has a 50 day simple moving average of $7.89 and a two-hundred day simple moving average of $7.67.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Cartesian Therapeutics in a research report on Wednesday, September 9th. Wall Street Zen upgraded shares of Cartesian Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th. Needham & Company LLC reissued a "buy" rating and issued a $40.00 target price on shares of Cartesian Therapeutics in a research note on Tuesday, September 29th. Wedbush restated an "outperform" rating and set a $38.00 price target on shares of Cartesian Therapeutics in a research report on Tuesday, August 18th. Finally, HC Wainwright restated a "buy" rating and set a $25.00 price target on shares of Cartesian Therapeutics in a research report on Wednesday, September 30th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $32.60.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc NASDAQ: RNAC is a clinical-stage biotechnology company focused on developing mRNA cell therapies for autoimmune diseases. The company's platform is designed to program a patient's own immune cells with messenger RNA, enabling the development of cell therapies that are intended to provide targeted treatment without permanent genetic modification.

Cartesian's lead product candidate is Descartes-08, an autologous CAR T-cell therapy that targets B-cell maturation antigen (BCMA).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.